← Eichor
Condition: Sensitive Skin Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Sensitive Skin

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
Phase 2 · 12 location(s) · Alphyn Biologics · NCT06855745Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Level
Phase 2 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT03835767Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks
NA · 1 location(s) · Pierre Fabre Dermo Cosmetique · NCT07014007Diagnosis and Allergen Identification of Perioperative Anaphylaxis
Phase N/A · 6 location(s) · Peking University First Hospital · NCT06793163Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Phase 2 · 62 location(s) · Janssen Research & Development, LLC · NCT07230860This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate
Phase N/A · 59 location(s) · Sanofi · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2 · 23 location(s) · Enveda Therapeutics · NCT07298395Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
Phase N/A · 1 location(s) · University Hospital Schleswig-Holstein · NCT03361215Multi-modal Quantitative Imaging of the Skin
Phase N/A · 3 location(s) · HJN Sverige AB/Neko Health · NCT06989216Determinants of Chronic Inflammatory Skin Disease Trajectories
Phase N/A · 1 location(s) · University Hospital Schleswig-Holstein · NCT05928169Quercus Ilex and Quercus Robur Allergen Extracts Standardisation
NA · 1 location(s) · Inmunotek S.L. · NCT05532566FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Phase 1 · 5 location(s) · Pfizer · NCT06564389The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance
Phase N/A · 1 location(s) · Copenhagen University Hospital, Hvidovre · NCT06224634Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
NA · 2 location(s) · Jessa Hospital · NCT04979078Drug Survival of Target Therapies in Atopic Dermatitis
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06882148Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Tre
Phase 3 · 23 location(s) · Octapharma · NCT06361537Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe At
Phase 2 · 99 location(s) · Novartis Pharmaceuticals · NCT06947993Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Phase 4 · 4 location(s) · Johann E Gudjonsson MD PhD · NCT06906497Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associat
Phase 1 · 1 location(s) · Akros Pharma Inc. · NCT07247266Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
Phase 1 · 8 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06504160Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
Phase N/A · 2 location(s) · King's College London · NCT06468124Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended En
Phase N/A · 12 location(s) · Shengjing Hospital · NCT04476485Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
Phase N/A · 2 location(s) · Centre hospitalier de l'Université de Montréal (CHUM) · NCT04198740Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arterit
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT05479448Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
NA · 1 location(s) · NAOS Les Laboratoires · NCT06756438A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
Phase 1 · 1 location(s) · Jiangsu Genscend Biopharmaceutical Co., Ltd · NCT07411755Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Phase N/A · 1 location(s) · Zhongda Hospital · NCT07573735Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi
Phase 1 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07262983Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy
Phase N/A · 9 location(s) · Fundación Academia Española de Dermatología · NCT05674695
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.